Growth factor supportive care for chemotherapy-induced neutropenia suppresses antitumour immunity in checkpoint blockade-responsive pancreatic cancer
Immunotherapy Advances · 31.12.2025 · 6 (1)
DOI: 10.1093/immadv/ltag013 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunotherapy Advances, online erschienen am 15.07.2026. Verfasst von Brendan D Parent und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIAID NIH HHS, Hale Center for Pancreatic Cancer Research.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Introduction
Growth factors, including granulocyte colony-stimulating factor (G-CSF; pegfilgrastim, filgrastim), are used for prophylaxis or treatment of chemotherapy-induced neutropenia, yet their effects on antitumour immunity remain incompletely understood. We previously found that serum from patients with pancreatic ductal adenocarcinoma (PDAC) treated with multiagent chemotherapy plus G-CSF drove differentiation of T cell-suppressive monocytes in vitro, suggesting that supportive care interventions may shape immune responses in this disease.
Methods
We evaluated the immunologic and therapeutic impact of G-CSF in two murine PDAC models that differ in their baseline frequencies of infiltrating T cells and in their responsiveness to checkpoint blockade immunotherapy.
Results
In poorly immunogenic, T-cell-low tumours, use of G-CSF did not affect tumour growth or response to chemo- or immunotherapy, although neutrophil recovery was improved in mice receiving FOLFIRINOX and G-CSF compared to chemotherapy alone. In immunogenic tumours with a robust endogenous T-cell response, combination anti-PD1 and anti-CTLA-4 therapy resulted in durable tumour clearance. Combination with G-CSF diminished the effectiveness of checkpoint blockade and resulted in significantly fewer cured mice.
Conclusion
G-CSF, commonly used for supportive care with FOLFIRINOX and other chemotherapy regimens, induces systemic immune suppression that can reduce the efficacy of T-cell-targeting immunotherapies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
- Amherst College, Amherst, MA, USA.
- Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA.
- Department of Immunology, Harvard Medical School, 350 Longwood Ave, Boston, MA 02115, USA.
- Department of Medicine, Division of Gastroenterology, Massachusetts General Hospital, Boston, MA, USA.
- Department of Medicine, Harvard Medical School, Boston, MA, USA.
ORCID-Profile: Brendan D Parent, Stephanie K Dougan
Förderung
- NCI NIH HHS
- NIAID NIH HHS
- Hale Center for Pancreatic Cancer Research
- Break Through Cancer
- Ludwig Center at Harvard
- National Institutes of Health
- Parker Institute for Cancer Immunotherapy
- Peter and Ann Lambertus Family Foundation
Zitieren
APA
Parent, B. D., Kelly, A. E., Hoffman, M. T., Dougan, M., Aguirre, A. J., & Dougan, S. K. (2025). Growth factor supportive care for chemotherapy-induced neutropenia suppresses antitumour immunity in checkpoint blockade-responsive pancreatic cancer. Immunotherapy Advances, 6(1). https://doi.org/10.1093/immadv/ltag013
Vancouver
Parent BD, Kelly AE, Hoffman MT, Dougan M, Aguirre AJ, Dougan SK. Growth factor supportive care for chemotherapy-induced neutropenia suppresses antitumour immunity in checkpoint blockade-responsive pancreatic cancer. Immunotherapy Advances. 2025;6(1). doi:10.1093/immadv/ltag013
BibTeX
@article{Parent2025,
author = {Parent, Brendan D and Kelly, Anthony E and Hoffman, Megan T and Dougan, Michael and Aguirre, Andrew J and Dougan, Stephanie K},
title = {Growth factor supportive care for chemotherapy-induced neutropenia suppresses antitumour immunity in checkpoint blockade-responsive pancreatic cancer},
journal = {Immunotherapy Advances},
year = {2025},
volume = {6},
number = {1},
doi = {10.1093/immadv/ltag013}
}
EUVIMED